Nutraceuticals & Supplement Premix Manufacturer

Our nutraceutical and supplement premixes are formulated for hard capsule fills, tablet blends, sachets, ready-to-drink (RTD) powder formats, gummies, and softgels. Particle size distribution, flowability, and hygroscopicity are optimised for the specific delivery format at prototype stage — before any commercial commitment. If your target format has specific tableting or encapsulation requirements, share them with us and we will incorporate them into the formulation brief.

Every commercial batch is analytically validated for label claim potency through NABL-accredited third-party testing before dispatch. Our PLC-controlled automated blending lines maintain ≥99% batch uniformity, and accelerated stability data confirms that label-claim potency is maintained throughout the declared shelf life — not just at the time of manufacture. You receive a full Certificate of Analysis with every shipment.

Yes. All custom formulation development work is covered by a Non-Disclosure Agreement (NDA) before any technical discussions begin. Your proprietary formulation remains yours — we manufacture it under NDA, do not share it with other clients, and provide full documentation that stays with you. We also supply premixes under our NutraX brand for brands who prefer to keep the supplier relationship confidential.

We prepare a full FSSAI Health Supplements & Nutraceuticals dossier package — including ingredient permissibility verification, label claim compliance review, product categorisation under FSS Act 2006, CoAs, specification sheets, and stability summaries. Our team has experience with FSSAI product registration for supplement brands and can support you through the submission process, including responding to regulatory queries.

A typical timeline runs 8–10 weeks from formula lock to first commercial batch: 4–6 weeks for lab prototype development and initial analytical validation, followed by 4–6 weeks for scale-up and commercial batch preparation. Regulatory dossier preparation can run in parallel. If you already have a formulation specification, the development phase is shorter — contact us with your brief and we will confirm the timeline for your specific project.

Yes. Accelerated stability studies (40°C / 75% RH) begin with the first prototype batch and continue in parallel with scale-up. This means you have real stability data to support label-claim and shelf-life declarations before commercial launch — not after. Real-time confirmation studies run in parallel to build the full shelf-life dossier over time.